ICP DAS to Showcase AI-Powered Intelligent Traffic Control Solutions at APTA 2026 TRANSform & EXPO
HSINCHU, Sept. 22, 2026 /PRNewswire/ -- ICP DAS will showcase its latest intelligent transportation technologies at APTA 2026 TRANSform & EXPO, taking place October 4–7 at McCormick Place in Chicago, Illinois. Visitors are invited to Booth 4625...
FDA Approves Telix's Brain Cancer Imaging Drug Pixclara
Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer). Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatment-related change in adults and...
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients. Telix has positively engaged with the FDA on a New Drug Application (NDA) pathway in the U.S. that...
Scientific forum in Singapore explores advanced PET/CT imaging
SINGAPORE, May 28, 2026 /PRNewswire/ -- Singapore General Hospital (SGH), a leading academic medical centre in Singapore, on May 21 hosted "Advancing Precision Imaging with Next Generation PET/CT," a scientific forum that brought together experts in...
Investor Education Webinar
The Future of Prostate Imaging: What do physicians want? MELBOURNE, Australia and INDIANAPOLIS, March 2, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") invites investors to join a webinar with key opinion leaders...
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
MELBOURNE, Australia and INDIANAPOLIS, Jan. 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate...
SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging
Highlights Topline data from Clarity's diagnostic Phase II trial, SABRE, showed that 64Cu-SAR-Bombesin was safe, well tolerated and effective at detecting prostate cancer in patients with biochemical recurrence (BCR) who are negative or equivocal on...
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia...
Athinoula A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital Chooses a United Imaging Next Generation PET/CT to Revolutionize the Study of Systems Physiology
HOUSTON, Jan. 28, 2025 /PRNewswire/ -- As pioneers in biomedical imaging and neuroscience, the researchers at the Athinoula A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital (MGH), a founding member of the Mass General...
XingImaging Opens State-of-the-Art Research Facility in New Haven, Connecticut
NEW HAVEN, Conn., Jan. 13, 2025 /PRNewswire/ -- XingImaging, a MITRO company, a leader in advanced research imaging and radiopharmaceutical services, is excited to announce the opening of its new state-of-the art research facility in New Haven,...